Free, research-backed cannabis education for adults 21+ Not medical advice · No product sales · For Clinicians

Other Conditions

Emerging research on cannabis for additional health conditions — where the science is still catching up to patient interest.

Limited Evidence

Overview

Beyond the conditions covered in our dedicated pages — anxiety, chronic pain, insomnia, inflammation, nausea & appetite, PTSD, and epilepsy — people use cannabis for a wide range of other health conditions. For most of these, the evidence is limited, mostly preclinical (lab and animal studies), or primarily anecdotal.

We believe you deserve an honest picture of where research stands for each of these conditions, even when the honest answer is "we don't know enough yet." Being transparent about the limits of current evidence is just as important as highlighting what the research supports.

Key takeaway: For the conditions on this page, the evidence ranges from early but intriguing to mostly anecdotal. If you are considering cannabis for any of these conditions, work closely with a healthcare provider and keep your expectations realistic. Promising preclinical results do not always translate to proven clinical benefits.

Multiple Sclerosis (MS)

What the Research Says

Multiple sclerosis is a chronic autoimmune condition where the immune system attacks the protective covering of nerves, causing communication problems between the brain and the rest of the body. Symptoms can include muscle spasticity, pain, fatigue, and bladder dysfunction.

MS is one of the better-studied conditions in cannabis medicine, largely due to a specific pharmaceutical product:

  • Sativex (nabiximols): An oromucosal spray containing a roughly 1:1 ratio of THC and CBD, Sativex is approved in over 25 countries (including the UK, Canada, and several European nations) for the treatment of MS-related spasticity. It is not currently approved in the United States, though clinical trials have been conducted here.
  • Clinical trial evidence: Multiple randomized controlled trials have shown that nabiximols significantly reduces self-reported spasticity scores compared to placebo, with a meaningful proportion of patients achieving at least a 20% improvement in spasticity.
  • Pain and sleep: Patients using nabiximols for spasticity have also reported secondary improvements in pain and sleep quality.

Nabiximols (Sativex) is approved in over 25 countries for MS-related spasticity, making it one of the few cannabis-based medications with multinational regulatory approval for a specific indication.

Multiple clinical trials and regulatory reviews

Practical Considerations

Since Sativex is not available in the US, American patients with MS who want to explore cannabis typically work through their state's medical cannabis program (MS is a qualifying condition in many states). A balanced THC:CBD product and consultation with a neurologist are recommended starting points.

Crohn's Disease & Inflammatory Bowel Disease (IBD)

What the Research Says

Crohn's disease and ulcerative colitis are forms of inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, causing symptoms like abdominal pain, severe diarrhea, fatigue, and weight loss.

  • Biological rationale: The gastrointestinal tract has a high concentration of CB2 receptors (part of the endocannabinoid system), which are involved in regulating immune function and inflammation. This provides a plausible biological basis for why cannabinoids might help.
  • Symptom relief vs. disease modification: Several observational studies and small clinical trials suggest that cannabis can improve symptoms in IBD patients — particularly pain, appetite, nausea, and diarrhea. However, there is limited evidence that cannabis reduces the underlying intestinal inflammation itself.
  • A key 2018 study: A randomized controlled trial of cannabis cigarettes in Crohn's disease found significant clinical improvement and better quality of life scores compared to placebo, but no improvement in objective inflammatory markers (like CRP or endoscopic findings).
  • Patient surveys: Surveys of IBD patients who use cannabis consistently report high rates of symptom improvement, particularly for pain and appetite.

Practical Considerations

If you have IBD, continue working with your gastroenterologist. Cannabis may help manage symptoms, but should not replace disease-modifying therapies (immunomodulators, biologics) that address the underlying inflammation. Smoking is generally discouraged for IBD patients; tinctures or edibles are preferred delivery methods.

Fibromyalgia

What the Research Says

Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties (often called "fibro fog"). It is notoriously difficult to treat, and many patients cycle through multiple medications with limited success.

  • Endocannabinoid deficiency theory: Neurologist Dr. Ethan Russo has proposed that fibromyalgia may be linked to clinical endocannabinoid deficiency (CECD) — an underperforming endocannabinoid system. If this theory is correct, supplementing with phytocannabinoids could address a root cause rather than just masking symptoms. However, this theory remains unproven.
  • Patient survey data: Surveys consistently show that fibromyalgia patients who use cannabis report improvements in pain, sleep, and overall quality of life. A significant number report reducing or discontinuing other medications.
  • Clinical evidence: A few small clinical trials and observational studies support symptom improvement, but the evidence base remains limited by small sample sizes and study design limitations.
  • The 2025 OHSU review note: The finding that CBD-only products showed minimal pain benefit is relevant here — fibromyalgia patients may need products containing THC (or a combination of cannabinoids) rather than CBD alone.

Practical Considerations

If you have fibromyalgia and want to explore cannabis, start with very low doses and consider a balanced THC:CBD product. Many fibromyalgia patients report that different symptoms respond to different approaches — a daytime microdose for pain and fog, and a slightly higher dose in the evening for sleep. Keep detailed records of what helps and what does not.

Parkinson's Disease

What the Research Says

Parkinson's disease is a progressive neurological disorder that affects movement, causing tremors, stiffness, slowness of movement, and balance problems. As it progresses, it can also cause sleep disturbances, depression, anxiety, and cognitive changes.

  • Preclinical promise: Laboratory and animal studies have shown that cannabinoids have neuroprotective properties and can reduce neuroinflammation, which is involved in Parkinson's progression. CBD in particular has shown neuroprotective effects in animal models.
  • Symptom management: Small clinical studies and patient surveys suggest cannabis may help with several Parkinson's symptoms, including tremor, rigidity, pain, sleep disturbances, and anxiety. However, the clinical trial data is very limited.
  • REM sleep behavior disorder: A small study found that CBD improved symptoms of REM sleep behavior disorder (a condition common in Parkinson's where patients physically act out their dreams), but this requires replication in larger trials.
  • No evidence of disease modification: There is currently no evidence from human studies that cannabis slows, stops, or reverses the progression of Parkinson's disease.

Practical Considerations

Parkinson's patients should work closely with their neurologist before trying cannabis. Drug interactions with Parkinson's medications (particularly levodopa and dopamine agonists) have not been thoroughly studied. Balance and fall risk are important considerations, as THC can cause dizziness. Start with very low doses and avoid inhalation if motor coordination is already impaired.

Cancer (Beyond Nausea)

What the Research Says

Cannabis is well-established for managing chemotherapy-induced nausea and appetite loss (covered on our Nausea & Appetite page). But what about cancer itself? Can cannabis fight tumors?

  • Preclinical findings: Laboratory studies have shown that cannabinoids (particularly THC and CBD) can inhibit tumor cell growth, promote cancer cell death (apoptosis), and reduce the ability of tumors to form new blood vessels (angiogenesis) in cell cultures and animal models. These results have been observed across multiple cancer types, including breast, lung, colon, prostate, and brain cancers.
  • The critical caveat: These are preclinical results. What happens in a petri dish or a mouse does not necessarily translate to what happens in the human body. Many substances that kill cancer cells in the lab fail to work as cancer treatments in humans. There are currently no completed large-scale clinical trials demonstrating that cannabis can treat or cure any form of cancer in humans.
  • Ongoing research: Small clinical trials are underway, and a notable study found that adding a THC:CBD combination to temozolomide (a chemotherapy drug) showed a trend toward improved survival in patients with recurrent glioblastoma (an aggressive brain cancer). However, the trial was small and the results, while encouraging, are not conclusive.

While preclinical studies show cannabinoids can inhibit tumor growth in laboratory settings, there are currently no completed large-scale clinical trials demonstrating that cannabis can treat or cure any form of cancer in humans.

Multiple preclinical reviews

Practical Considerations

Be very cautious about claims that cannabis cures cancer. This is an area where misinformation is rampant, and people in desperate situations are vulnerable to false hope. Cannabis can meaningfully improve quality of life during cancer treatment (managing nausea, pain, appetite, sleep, and anxiety), but it should not be used as a substitute for proven cancer treatments like surgery, chemotherapy, radiation, or immunotherapy. Always discuss cannabis use with your oncologist.

Autism Spectrum Disorder (ASD)

What the Research Says

Interest in cannabis for autism spectrum disorder has grown significantly among parents and caregivers, particularly for managing challenging behavioral symptoms like aggression, self-injury, severe anxiety, and sleep disturbances.

  • Emerging observational data: Several observational studies, primarily from Israel, have reported improvements in behavioral symptoms, anxiety, communication, and sleep in children and adults with ASD who used cannabis-based products (typically CBD-dominant). One study of 188 ASD patients found that after six months of treatment with CBD-rich cannabis oil, over 30% reported significant improvement and another 53% reported moderate improvement.
  • Biological rationale: Some research suggests that the endocannabinoid system may be altered in people with ASD, providing a theoretical basis for cannabinoid therapy. However, this research is in its early stages.
  • Very limited clinical trial data: There are few randomized controlled trials. The available evidence is primarily observational, and the studies that exist are generally small and lack the rigor needed to draw definitive conclusions.
  • Ethical complexity: Much of the interest involves treating children, which raises additional ethical and safety considerations. Long-term effects of cannabinoid use on the developing brain are not well understood.

Practical Considerations

If you are considering cannabis for a family member with ASD, work with a physician experienced in both ASD and cannabinoid medicine. CBD-dominant products are generally preferred due to a more favorable side effect profile and the concerns about THC's effects on brain development, especially in children and adolescents. This is an area where the gap between patient/caregiver interest and rigorous scientific evidence is particularly wide.

Risks & Considerations

For all conditions on this page, the following general cautions apply:

  • Limited evidence means more uncertainty. When the evidence is early or primarily preclinical, there is a wider range of possible outcomes — including the possibility that cannabis may not help, or could make things worse.
  • Do not replace proven treatments. For serious conditions like MS, cancer, Parkinson's, and epilepsy, established medical treatments exist. Cannabis should be considered as a potential complement, not a replacement, unless your physician specifically advises otherwise.
  • Drug interactions are a real concern. Many of the conditions on this page involve medications that can interact with cannabinoids through the CYP450 enzyme system. Review our Drug Interactions page and discuss all medications with your provider.
  • Quality matters. For serious medical conditions, the purity, potency, and consistency of cannabis products are especially important. Look for products with third-party lab testing and certificates of analysis.
  • Be skeptical of miracle claims. If someone tells you cannabis is a guaranteed cure for any of these conditions, that claim is not supported by current evidence. Honest information serves you better than false hope.

Talk to Your Doctor

For any of the conditions on this page, the conversation with your healthcare provider is essential. Many of these conditions involve complex treatment regimens, and adding cannabis requires professional guidance.

Conversation starters:

  • "I've been reading about cannabis research for [condition]. I know the evidence is still early, but I'd like to discuss whether it might be worth exploring as a complement to my current treatment."
  • "I want to be transparent that I'm interested in trying cannabis, and I need to understand how it might interact with my current medications."
  • "I understand there isn't strong clinical trial evidence yet for cannabis and [condition]. But given that my current treatments aren't fully managing my symptoms, are there any safe ways to explore this?"

If your provider is not knowledgeable about cannabis, the Society of Cannabis Clinicians and Leaf411 can help connect you with professionals who are.

Further Reading